nach oben

Erschienen in:

01.10.2013 | Fortbildung

Immunmodulierende Injektionstherapien in der Langzeitbehandlung

Multiple Sklerose

verfasst von: Dr. med. Antonios Bayas, Prof. Dr. med. Mathias Mäurer

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Zeitalter der Entwicklung vieler neuer Therapieprinzipien stellt sich die Frage nach der Zukunft der injizierbaren Therapeutika wie Beta-Interferone und Glatirameracetet, die sich als Basistherapien der ersten Wahl der schubförmigen multiplen Sklerose seit langem fest etabliert haben. Sie haben im Vergleich zu den erst kürzer zugelassenen oder vor der Zulassung stehenden Präparaten, den großen Vorteil gut bekannter Langzeitverträglichkeit und -sicherheit. Diese Aspekte spielen in der Beratung der Patienten oft eine sehr wichtige Rolle.

Paty DW and Li DK (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662–667PubMedCrossRef

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, BourdetteT DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, III, Priore RL, Pullicino PM, Scherokman BJ, and Whitham RH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294PubMedCrossRef

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504CrossRef

O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 Oct;8:889–897.PubMedCrossRef

Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002 Nov 26;59:1507–1517.PubMedCrossRef

Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005 Dec 15;239:67–74.PubMedCrossRef

Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 Apr 27;359:1453–1460.PubMedCrossRef

Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 Aug 4;370:389–397.PubMedCrossRef

Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000 Sep 28;343:898–904.PubMedCrossRef

10.

Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012 Jan;11(1):33–41PubMedCrossRef

11.

Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, and Dahlke F (2001) Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 57:1969–1975PubMedCrossRef

12.

SPECTRIMS Study Group (2001) Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 56:1496–1504CrossRef

13.

DGN / KKNMS Leitlinie zur Diagnose und Therapie der MS — Online Version, Stand: 09.08.2012. In, 2012.

14.

Trojano M, Pellegrini F, Fuiani A et al. New natural history of interferon- beta-treated relapsing multiple sclerosis. Ann Neurol. 2007;61(4):300–306.PubMedCrossRef

15.

Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology. 2012 Apr 24;78(17):1315–1322PubMedCrossRef

16.

Shirani A, Zhao Y, Karim ME et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308(3):247–256.PubMedCrossRef

17.

Mäurer M, Dachsel R, Domke S, Ries S, Reifschneider G, Friedrich A, Knorn P, Landefeld H, Niemczyk G, Schicklmaier P, Wernsdörfer C, Windhagen S, Albrecht H, Schwab S; for the TYPIC Study Investigators. Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. Eur J Neurol. 2011 Aug;18(8):1036–1045.PubMedCrossRef

18.

Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf 2000;22:149–159.PubMedCrossRef

19.

Racke MK, Lovett-Racke AE. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J Immunol 2011;186:1887–1890.PubMedCrossRef

20.

Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408–414.PubMedCrossRef

21.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268–1276.PubMedCrossRef

22.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701–708.PubMedCrossRef

23.

Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290–297.PubMedCrossRef

24.

Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into „black holes“. Neurology 2001;57:731–733.PubMedCrossRef

25.

Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006;253:1160–1164.PubMedCrossRef

26.

Wolinsky JS, Narayana PA, O’ Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14–24.PubMedCrossRef

27.

Filippi M, Wolinsky JS, Comi G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006;5:213–220.PubMedCrossRef

28.

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 2011;69:75–82.PubMedCrossRef

29.

Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013.

30.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503–1511.PubMedCrossRef

31.

O’ Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, O’ Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889–897.CrossRef

32.

Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903–914.PubMedCrossRef

33.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976–1983.PubMedCrossRef

34.

Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342–350.PubMedCrossRef

35.

Veugelers PJ, Fisk JD, Brown MG, Stadnyk K, Sketris IS, Murray TJ, Bhan V. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult Scler 2009;15:1286–1294.PubMedCrossRef

36.

Boster A, Bartoszek MP, O’ Connell C, Pitt D, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2011;4:319–332.PubMedCrossRef

37.

Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58–63.PubMed

38.

Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 2008;255 Suppl 6:87–92.PubMedCrossRef

39.

Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv 2013;10:285–287.PubMedCrossRef

40.

Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J, Jeffery D, Cohen B, Mankowski K, Guarnaccia J, Schaeffer L, Kanter R, Brandes D, Kaufman C, Duncan D, Marder E, Allen A, Harney J, Cooper J, Woo D, Stuve O, Racke M, Frohman EM. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568–576.PubMedCrossRef

Titel: Immunmodulierende Injektionstherapien in der Langzeitbehandlung
Multiple Sklerose
verfasst von: Dr. med. Antonios Bayas
Prof. Dr. med. Mathias Mäurer
Publikationsdatum: 01.10.2013
Verlag: Urban & Vogel
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 10/2013
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-013-0424-z

Neu in den Fachgebieten Neurologie und Psychiatrie

25.04.2024 | Hypotonie | Nachrichten

Springer Medizin

Immunmodulierende Injektionstherapien in der Langzeitbehandlung

Multiple Sklerose

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2013

Hecken rechnet mit Klagen gegen den GBA

Zwei Jahre Fingolimod bei MS

Die einfache Welt der MS-Therapie: Ende einer Ära

Hat die Kombination von Interferon und Glatirameracetat Vorteile gegenüber der Monotherapie?

So drucken Praxen direkt vom Tablet

Bei älteren Patienten häufig falsche Erstdiagnose

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe